AstraZeneca’s Imfinzi Scores Neoadjuvant/Adjuvant NSCLC Two-fer At AACR

 
• By Alaric DeArment
  
Lung Cancer
AstraZeneca announced data for Imfinzi in neoadjuvant/adjuvant non-small cell lung cancer at AACR • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D